PNC-27

• ⚠️ READ FIRST: PNC-27 is an unapproved experimental anticancer peptide that the FDA has explicitly WARNED against — products have been found bacterially contaminated, and there is NO verified human clinical trial data. It must never be treated as a usable cancer therapy.
• It is a 32-amino-acid chimeric peptide: a p53/HDM-2-binding domain fused to a membrane-penetrating sequence (penetratin). In cell studies it selectively lyses cancer cells that display HDM-2 on their membrane, reportedly sparing normal cells.
• All efficacy evidence is in vitro/preclinical. Secondary-source claims of human use exist but have no verifiable trial registrations or peer-reviewed results.
• Anyone facing cancer should consult a qualified oncologist and rely on FDA-approved treatments — this profile is for research context only.

PNC-27 is an experimental anticancer peptide designed in 2000 (Pincus & Michl, SUNY Downstate) by combining the HDM-2 (MDM2)-binding region of the tumor-suppressor p53 with a membrane-penetrating peptide. In cell culture it appears to selectively kill cancer cells by forming pores in their membranes.

This is the one profile where the warning comes before the science. The FDA has issued explicit warnings about PNC-27 products, including documented bacterial contamination, and there is no verified human safety or efficacy data of any kind. Nothing here is medical advice, and PNC-27 is not a treatment — it is an unproven, FDA-flagged research chemical.

PNC-27 is a 32-amino-acid chimeric peptide (~4,032 Da). It fuses two functional parts: the p53 residues (12–26) that bind HDM-2/MDM2, and a penetratin/Antennapedia-derived membrane-resident peptide (MRP) that lets it associate with cell membranes. Research indicates the chimeric linkage is essential — neither domain alone reproduces the effect.

The proposed mechanism: PNC-27 binds HDM-2 that is expressed on the membrane of cancer cells, forming oligomeric transmembrane pores that cause rapid necrotic death. Normal cells reportedly lack membrane HDM-2 and are spared, and the effect is described as independent of the cell's p53-mutation status. A 2024 study describes a secondary intracellular mechanism involving disruption of mitochondrial membranes. All of this is from cell-line work — none of it is validated in humans.

• Landmark study (PNAS, 2010): in pancreatic/breast/melanoma cell lines, PNC-27 caused necrosis (IC50 ~33 µM, ~90 min to full kill) via transmembrane pores on membrane HDM-2, sparing normal fibroblasts.
• Mechanism (2010): the chimeric linkage is required — the p53 domain and the membrane peptide each fail alone.
• Leukemia selective necrosis (2014): killed K562/U937/HL60 lines (IC50 ~4.7–91 µM) without affecting normal lymphocytes; death was necrotic, not apoptotic.

Every result is in cell culture. There is no verified human trial — claims to the contrary lack trial registrations (NCT numbers) or peer-reviewed outcomes.

There is no human safety profile and no human pharmacokinetics for PNC-27. The FDA has issued explicit warnings about PNC-27 products, and bacterial contamination (Variovorax paradoxus) has been documented in marketed material — the FDA specifically flagged contaminated inhalable/nebulized products, a route that should be avoided entirely. Any vendor 'cancer cure' claim is unsubstantiated. PNC-27 should never replace FDA-approved cancer treatment, and anyone considering it should consult a qualified oncologist first.

PNC-27 is not FDA-approved for any use, and the FDA has warned against PNC-27 products. It is sold only as a research chemical, not intended for human consumption, and carries documented contamination risk.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.